These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 28632743)

  • 1. In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles.
    Luo C; Wang K; Zhang H
    PLoS One; 2017; 12(6):e0179515. PubMed ID: 28632743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the effects of quinidine, disopyramide, and E-4031 on short QT syndrome variant 3 in the human ventricles.
    Luo C; Wang K; Zhang H
    Physiol Meas; 2017 Sep; 38(10):1859-1873. PubMed ID: 28812984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of amiodarone on short QT syndrome variant 3 in human ventricles: a simulation study.
    Luo C; Wang K; Zhang H
    Biomed Eng Online; 2017 Jun; 16(1):69. PubMed ID: 28592292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles.
    Whittaker DG; Ni H; Benson AP; Hancox JC; Zhang H
    Front Physiol; 2017; 8():759. PubMed ID: 29085299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased vulnerability of human ventricle to re-entrant excitation in hERG-linked variant 1 short QT syndrome.
    Adeniran I; McPate MJ; Witchel HJ; Hancox JC; Zhang H
    PLoS Comput Biol; 2011 Dec; 7(12):e1002313. PubMed ID: 22194679
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Whittaker DG; Hancox JC; Zhang H
    Front Physiol; 2018; 9():1888. PubMed ID: 30687112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapeutic Effects of Quinidine on Short QT Syndrome by Using Purkinje-Ventricle Model: A Simulation Study.
    Luo C; Whittaker DG; Liu T; Wang K; Li Y; He Y; Zhang H
    Annu Int Conf IEEE Eng Med Biol Soc; 2019 Jul; 2019():2856-2859. PubMed ID: 31946488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility.
    Odening KE; Bodi I; Franke G; Rieke R; Ryan de Medeiros A; Perez-Feliz S; Fürniss H; Mettke L; Michaelides K; Lang CN; Steinfurt J; Pantulu ND; Ziupa D; Menza M; Zehender M; Bugger H; Peyronnet R; Behrends JC; Doleschall Z; Zur Hausen A; Bode C; Jolivet G; Brunner M
    Eur Heart J; 2019 Mar; 40(10):842-853. PubMed ID: 30496390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome.
    McPate MJ; Duncan RS; Witchel HJ; Hancox JC
    J Mol Cell Cardiol; 2006 Sep; 41(3):563-6. PubMed ID: 16842817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo effects of mutant HERG K+ channel inhibition by disopyramide in patients with a short QT-1 syndrome: a pilot study.
    Schimpf R; Veltmann C; Giustetto C; Gaita F; Borggrefe M; Wolpert C
    J Cardiovasc Electrophysiol; 2007 Nov; 18(11):1157-60. PubMed ID: 17711440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome.
    Patel C; Antzelevitch C
    Heart Rhythm; 2008 Apr; 5(4):585-90. PubMed ID: 18362027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study.
    McPate MJ; Zhang H; Adeniran I; Cordeiro JM; Witchel HJ; Hancox JC
    J Physiol Pharmacol; 2009 Mar; 60(1):23-41. PubMed ID: 19439805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of the β-adrenoceptor blockers carvedilol and metoprolol on SQT1- and SQT2-mutant channels.
    Bodi I; Franke G; Pantulu ND; Wu K; Perez-Feliz S; Bode C; Zehender M; zur Hausen A; Brunner M; Odening KE
    J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1163-71. PubMed ID: 23718892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proarrhythmia in KCNJ2-linked short QT syndrome: insights from modelling.
    Adeniran I; El Harchi A; Hancox JC; Zhang H
    Cardiovasc Res; 2012 Apr; 94(1):66-76. PubMed ID: 22308236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the effects of amiodarone on short QT syndrome variant 2 in the human ventricles.
    Cunjin Luo ; Kuanquan Wang ; Henggui Zhang
    Annu Int Conf IEEE Eng Med Biol Soc; 2017 Jul; 2017():4273-4276. PubMed ID: 29060841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling Reentry in the Short QT Syndrome With Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets.
    Shinnawi R; Shaheen N; Huber I; Shiti A; Arbel G; Gepstein A; Ballan N; Setter N; Tijsen AJ; Borggrefe M; Gepstein L
    J Am Coll Cardiol; 2019 May; 73(18):2310-2324. PubMed ID: 31072576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repolarisation and vulnerability to re-entry in the human heart with short QT syndrome arising from KCNQ1 mutation--a simulation study.
    Zhang H; Kharche S; Holden AV; Hancox JC
    Prog Biophys Mol Biol; 2008; 96(1-3):112-31. PubMed ID: 17905416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the effects of chloroquine on
    Luo C; Wang K; Zhang H
    Oncotarget; 2017 Dec; 8(63):106511-106526. PubMed ID: 29290967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.
    El Harchi A; Melgari D; Zhang YH; Zhang H; Hancox JC
    PLoS One; 2012; 7(12):e52451. PubMed ID: 23300672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.